Immunotherapies currently in development for the treatment of type 1 diabetes

Bibliography

• Yoon JW, Jun HS. Autoimmune destruction of pancreatic beta cells. Am J Ther 2005;12(6):580-91
   PubMedGoogle Scholar
• George SE. Type I diabetes mellitu. N Engl J Med 1986;314(21):1360-8
   PubMedGoogle Scholar
• UK fifth highest in world for child type 1 diabetes, BBC News, Health. 2013. Available from: http://www.bbc.com/news/health-20875495
   Google Scholar
• Type 1 Diabetes facts. About JDRF, Fact Sheets. Available from: http://jdrf.org/about-jdrf/fact-sheets/type-1-diabetes-facts
   Google Scholar
• Corthay A. How do regulatory T Cells work? Scand J Immunol 2009;70(4):326-36
   PubMed Web of Science ®Google Scholar
• Cabrera SM, Rigby MR, Mirmira RG. Targeting regulatory T cells in the treatment of Type 1 diabetes mellitus. Curr Mol Med 2012;12(10):1261-72
   PubMed Web of Science ®Google Scholar
• Chen W1, Xie A, Chan L. Mechanistic basis of Immunotherapies for Type 1 diabetes. Transl Res 2013.161(4):217-29. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23348026
   Google Scholar
• Michels AW, von Herrath M. 2011 update: antigen specific therapy in type 1 diabetes. Curr Opin Endocrinol Diabetes Obes 2011;18(4):235-40
   PubMed Web of Science ®Google Scholar
• Lamb JR, Skidmore BJ, Green N, et al. Induction of tolerance in influenza virus-immune T lymphocyte clones with synthetic peptides of influenza hemagglutinin. J Exp Med 1983;157:1434-47
   PubMed Web of Science ®Google Scholar
• Levich JD, Parks DE, Weigle WO. Tolerance induction in antigen-specific helper T cell clones and lines in vitro. J Immunol 1985;135:873-8
   PubMed Web of Science ®Google Scholar
• Peakman M, Dayan CM. Antigen-specific immunotherapy for autoimmune disease: fighting fire with fire? Immunology 2001;104(4):361-6
   PubMed Web of Science ®Google Scholar
• Luo X, Herold KC, Miller SD. Immunotherapy of type 1 diabetes: where are we and where should we be going? Immunity 2010;32:488-99
   PubMed Web of Science ®Google Scholar
• Prasad S, Kohm AP, McMahon JS, et al. Pathogenesis of NOD diabetes is initiated by reactivity to the insulin B chain 9–23 epitope and involves functional epitope spreading. J Autoimmun 2012;39(4):347-53
   PubMed Web of Science ®Google Scholar
• Barker JL, Behar T, Li YX, et al. GABAergic cells and signals in CNS development. Perspect Dev Neurobiol 1998;5(2-3):305-22
   PubMedGoogle Scholar
• Ludvigsson J. Therapy with GAD in diabetes. Diabetes Metab Res Rev 2009;25(4):307-15
   PubMed Web of Science ®Google Scholar
• Okada Y, Taniguchi H, Schimada C. High concentration of GABA and high glutamate decarboxylase activity in rat pancreatic islets and human insulinoma. Science 1976;194:620-2
   PubMed Web of Science ®Google Scholar
• Atkinson MA, Kaufman DL, Campbell L, et al. Response of peripheral-blood mononuclear cells to glutamate decarboxylase in insulin-dependent diabetes. Lancet 1992;339:458-9
   PubMed Web of Science ®Google Scholar
• Baekkeskov S, Nielsen JH, Marner B, et al. Autoantibodies in newly diagnosed diabetic children immunoprecipitate human pancreatic islet cell proteins. Nature 1982;298:167-9
   PubMed Web of Science ®Google Scholar
• Tian J, Clare-Salzler M, Herschenfeld A, et al. Modulating autoimmune responses to GAD inhibits disease progression and prolongs islet graft survival in diabetes-prone mice. Nat Med 1996;2:1348-53
   PubMed Web of Science ®Google Scholar
• Tisch R, Liblau RS, Yang XD, et al. Induction of GAD65-specific regulatory T-cells inhibits ongoing autoimmune diabetes in nonobese diabetic mice. Diabetes 1998;47:894-9
   PubMed Web of Science ®Google Scholar
• Ludvigsson J, Faresjo M, Hjorth M, et al. GAD treatment and insulin secretion in recent-onset type 1 diabetes. N Engl J Med 2008;359:1909-20
   PubMed Web of Science ®Google Scholar
• Wherrett DK, Bundy B, Becker DJ, et al. Antigen-based therapy with glutamic acid decarboxylase (GAD) vaccine in patients with. recent-onset type 1 diabetes: a randomised double-blind trial. Lancet 2011;378:319-27
   PubMed Web of Science ®Google Scholar
• Thrower SL, James L, Hall W, et al. Proinsulin peptide immunotherapy in type 1 diabetes: report of a first-in-man Phase I safety study. Clin Exp Immunol 2009;155(2):156-65
   PubMed Web of Science ®Google Scholar
• Fan Y, Rudert WA, Grupillo M, et al. Thymus-specific deletion of insulin induces autoimmune diabetes. EMBO J 2009;28(18):2812-24
   PubMed Web of Science ®Google Scholar
• Nanto-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372(9651):1746-55
   PubMed Web of Science ®Google Scholar
• Sherr J, Sosenko J, Skyler JS, et al. Prevention of type 1 diabetes: the time has come. Nat Clin Pract Endocrinol Metab 2008;4(6):334-43
   PubMedGoogle Scholar
• Skyler JS. Update on worldwide efforts to prevent type 1 diabetes. Ann N Y Acad Sci 2008;1150:190-6
   PubMed Web of Science ®Google Scholar
• Skyler JS, Krischer JP, Wolfsdorf J, et al. Effects of oral insulin in relatives of patients with type 1 diabetes: the diabetes prevention trial-type 1. Diabetes Care 2005;28(5):1068-76
   PubMed Web of Science ®Google Scholar
• Bonifacio E, Ziegler AG, Klingensmith G, et al. Effects of high-dose oral insulin on immune responses in children at high risk for type 1 diabetes: the Pre-POINT randomized clinical trial. JAMA 2015;313(15):1541-9
   PubMed Web of Science ®Google Scholar
• Orban T, Farkas K, Jalahej H, et al. Autoantigen-specific regulatory T cells induced in patients with type 1 diabetes mellitus by insulin B-chain immunotherapy. J Autoimmun 2009
   Web of Science ®Google Scholar
• Walter M, Philotheou A, Bonnici F, et al. No effect of the altered peptide ligand NBI-6024 on beta-cell residual function and insulin needs in new-onset type 1 diabetes. Diab care 2009;32(11):2036-40
   PubMed Web of Science ®Google Scholar
• Näntö-Salonen K, Kupila A, Simell S, et al. Nasal insulin to prevent type 1 diabetes in children with HLA genotypes and autoantibodies conferring increased risk of disease: a double-blind, randomised controlled trial. Lancet 2008;372(9651):1746-55
   PubMed Web of Science ®Google Scholar
• Brudzynski K, Martinez V, Gupta RS. Immunocytochemical localization of heat-shock protein 60-related protein in beta-cell secretory granules and its altered distribution in non-obese diabetic mice. Diabetologia 1992;35:316-24
   PubMed Web of Science ®Google Scholar
• Ozawa Y, Kasuga A, Nomaguchi H, et al. Detection of autoantibodies to the pancreatic islet heat shock protein 60 in insulin-dependent diabetes mellitus. J Autoimmun 1996;9(4):517-24
   PubMed Web of Science ®Google Scholar
• Elias D, Meilin A, Ablamunits V, et al. Hsp60 peptide therapy of NOD mouse diabetes induces a Th2 cytokine burst and downregulates autoimmunity to various beta-cell antigens. Diabetes 1997;46:758-64
   PubMed Web of Science ®Google Scholar
• Elias D, Cohen IR. Peptide therapy for diabetes in NOD mice. Lancet 1994;343:704-6
   PubMed Web of Science ®Google Scholar
• Padmalayam I. The heat shock response: its role in pathogenesis of Type 2 diabetes and its complications, and implications for therapeutic intervention. Discov Med 2014;18(97):29-39
   PubMedGoogle Scholar
• Elias D, Avron A, Tamir M, Raz I. DiaPep277 preserves endogenous insulin production by immunomodulation in type 1 diabetes. Ann N Y Acad Sci 2006;1079:340-344
   Google Scholar
• Fischer B, Elias D, Bretzel RG, Linn T. Immunomodulation with heat shock protein DiaPep277 to preserve beta cell function in type 1 diabetes - an update. Expert Opin Biol Ther 2010;10:265-72
   PubMed Web of Science ®Google Scholar
• Huurman VA, van der Meide PE, Duinkerken G, et al. Immunological efficacy of heat shock protein 60 peptide DiaPep277 therapy in clinical type I diabetes. Clin Exp Immunol 2008;152:488-97
   PubMed Web of Science ®Google Scholar
• Raz I, Elias D, Avron A, et al. Beta-cell function in new-onset type 1 diabetes and immunomodulation with a heat-shock protein peptide (DiaPep277): a randomised, double-blind, phase II trial. Lancet 2001;358:1749-53
   PubMed Web of Science ®Google Scholar
• Huurman VA, Decochez K, Mathieu C, et al. Therapy with the hsp60 peptide DiaPep277 in C-peptide positive type 1 diabetes patients. Diabetes Metab Res Rev 2007;23:269-75
   PubMed Web of Science ®Google Scholar
• Raz I, Ziegler AG, Linn T, et al. Treatment of recent-onset type 1 diabetic patients with DiaPep277: results of a double-blind, placebocontrolled, randomized phase 3 trial. Diabetes Care 2014;37:1392-400
   PubMed Web of Science ®Google Scholar
• Liu JKH. The history of monoclonal antibody development – Progress, remaining challenges and future innovations. Ann Med Surg (Lond) 2014;3(4):113-16
   PubMedGoogle Scholar
• Woodle ES, Xu D, Zivin RA, et al. Phase I trial of a humanized, Fc receptor nonbinding OKT3 antibody, huOKT3γ1(Ala-Ala) in the treatment of acute renal allograft rejection. Transplantation 1999;68(5):608-16
   PubMed Web of Science ®Google Scholar
• Utset TO, Auger JA, Peace D, et al. Bluestone JA, Clark MR. Modified anti-CD3 therapy in psoriatic arthritis: a phase I/II clinical trial. J Rheumatol 2002;29:1907-13
   PubMed Web of Science ®Google Scholar
• Sherry N, Hagopian W, Ludvigsson J, et al. Teplizumab for treatment of type 1 diabetes (Protégé study): 1-year results from a randomised, placebo-controlled trial. Lancet 2011;378(9790):487-97
   PubMed Web of Science ®Google Scholar
• Hagopian W, Ferry RJJr, Sherry N, et al. Teplizumab preserves C-peptide in recent-onset type 1 diabetes: two-year results from the randomized, placebo-controlled Protégé trial. Diabetes 2013;62(11):3901-8
   PubMed Web of Science ®Google Scholar
• Herold KC, Gitelman SE, Ehlers MR, et al. Teplizumab (Anti-CD3 mAb) treatment preserves C-peptide responses in patients with new-onset type 1 diabetes in a randomized controlled trial. Diabetes 2013;62(11):3766-74
   PubMed Web of Science ®Google Scholar
• Aronson R, Gottlieb PA, Christiansen JS, et al. Low-dose otelixizumab anti-CD3 monoclonal antibody DEFEND-1 study: results of the randomized phase III study in recent-onset human type 1 diabetes. Diabetes Care 2014;37(10):2746-54
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Walter M, Mathieu C, et al. Four-year metabolic outcome of a randomised controlled CD3-antibody trial in recent-onset type 1 diabetic patients depends on their age and baseline residual beta cell mass. Diabetologia 2010;53(4):614-23
   PubMed Web of Science ®Google Scholar
• Keymeulen B, Vandemeulebroucke E, Ziegler A, et al. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005.352(25):2598-608 Available from: www.nejm.org
   Google Scholar
• Pescovitz MD. Rituximab, an anti-CD20 monoclonal antibody: history and mechanism of action. Am J Transplant 2006;6(5 Pt 1):859-66
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Krause-Steinrauf H, et al. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361(22):2143-52
   PubMed Web of Science ®Google Scholar
• Pescovitz MD, Greenbaum CJ, Bundy B, et al. B-lymphocyte depletion with rituximab and β-cell function: two-year results. Diabetes Care 2014;37(2):453-9
   PubMed Web of Science ®Google Scholar
• Mandrup-Poulsen T, Pickersgill LMS, Donath MY. Blockade of interleukin 1 in type 1 diabetes mellitus. Nat Rev Endocrinol 2010;6:158-66
   PubMed Web of Science ®Google Scholar
• Maedler K, Sergeev P, Ris F, et al. Glucose-induced beta cell production of IL-1beta contributes to glucotoxicity in human pancreatic islets. J Clin Invest 2002;110:851-60
   PubMed Web of Science ®Google Scholar
• Sandler S, Andersson A, Hellerstrom C. Inhibitory effects of interleukin 1 on insulin secretion, insulin biosynthesis, and oxidative metabolism of isolated rat pancreatic islets. Endocrinology 1987;121:1424-31
   PubMed Web of Science ®Google Scholar
• Yamada K, Takane-Gyotoku N, Yuan X, et al. Mouse islet cell lysis mediated by interleukin-1-induced Fas. Diabetologia 1996;39:1306-12
   PubMed Web of Science ®Google Scholar
• Spinas GA, Hansen BS, Linde S, et al. Interleukin 1 dose-dependently affects the biosynthesis of (pro)insulin in isolated rat islets of Langerhans. Diabetologia 1987;30:474-80
   PubMed Web of Science ®Google Scholar
• Dinarello CA, Simon A, van der Meer JW. Treating inflammation by blocking interleukin-1 in a broad spectrum of diseases. Nat Rev Drug Discov 2012;11:633-52
   PubMed Web of Science ®Google Scholar
• Moran A, Bundy B, Becker DJ, et al. Interleukin-1 antagonism in type 1 diabetes of recent onset: two multicentre, randomised, double-blind, placebo-controlled trials. Lancet 2013;381(9881):10
   PubMed Web of Science ®Google Scholar
• Pafili K, Papanas N, Maltezos E. Gevokizumab in type 1 diabetes mellitus: extreme remedies for extreme diseases? Expert Opin Investig Drugs 2014;23(9):1277-84
   PubMed Web of Science ®Google Scholar
• Cnop M, Welsh N, Jonas JC, et al. Mechanisms of pancreatic beta-cell death in type 1 and type 2 diabetes: many differences, few similarities. Diabetes 2005;54(Suppl 2):S97-107
   PubMedGoogle Scholar
• Cavelti-Weder C, Babians-Brunner A, Keller C, et al. Effects of gevokizumab on glycemia and inflammatory markers in type 2 diabetes. Diabetes Care 2012;35(8):1654-62
   PubMed Web of Science ®Google Scholar
• Skyler JS. The Compelling case for anti-CD3 in type 1 diabetes. Diabetes 2013;62(11):3656-7
   PubMed Web of Science ®Google Scholar
• Czajkowsky DM, Hu J, Shao Z, et al. Fc-fusion proteins: new developments and future perspectives. EMBO Mol Med 2012;4(10):1015-28
   PubMed Web of Science ®Google Scholar
• Yu K, Liu C, Kim BG, et al. Synthetic fusion protein design and applications. Biotechnol Adv 2015;33(1):155-64
   PubMed Web of Science ®Google Scholar
• Ruderman EM, Richard PM. The evolving clinical profile of abatacept (CTLA4–Ig): a novel co-stimulatory modulator for the treatment of rheumatoid arthritis. Arthritis Res Ther 2005;7(Suppl 2):S21-5
   PubMedGoogle Scholar
• Marelli-Berg FM, Okkenhaug K, Mirenda V. A two-signal model for T cell trafficking. Trends Immunol 2007;28:267-73
   PubMed Web of Science ®Google Scholar
• Bluestone JA, St. Clair EW, Turka LA. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 2006;24:233-8
   PubMed Web of Science ®Google Scholar
• Orban T, Bundy B, Becker DJ, et al. Co-stimulation modulation with abatacept in patients with recent-onset type 1 diabetes: a randomised double-masked controlled trial. Lancet 2011;378(9789):412-19
   PubMed Web of Science ®Google Scholar
• Herold KC. Anti-CD3 monoclonal antibody in new-onset type 1 diabetes mellitus. N Engl J Med 2002;346:1692-8
   PubMed Web of Science ®Google Scholar
• Keymeulen B. Insulin needs after CD3-antibody therapy in new-onset type 1 diabetes. N Engl J Med 2005;352:2598-608
   PubMed Web of Science ®Google Scholar
• Pescovitz MD. Rituximab, B-lymphocyte depletion, and preservation of beta-cell function. N Engl J Med 2009;361:2143-52
   PubMed Web of Science ®Google Scholar
• Rigby MR, DiMeglio LA, Rendell MS, et al. Targeting effector memory T cells with alefacept in new oncet type 1 diabetes: 12 month results from the T1DAL study. Lancet Diabetes Endocrinol 2013;1(4):284-94
   PubMed Web of Science ®Google Scholar
• Sakaguchi S, Yamaguchi T, Nomura T, et al. Regulatory T cells and immune tolerance. Cell 2008;133:775
   PubMed Web of Science ®Google Scholar
• Campbell DJ, Koch MA. Phenotypical and functional specialization of FOXP3+ regulatory T cells. Nat Rev Immunol 2011;11:119
   PubMed Web of Science ®Google Scholar
• Wing K, Sakaguchi S. Regulatory T cells exert checks and balances on self tolerance and autoimmunity. Nat Immunol 2010;11:7
   PubMed Web of Science ®Google Scholar
• Brusko TM, Wasserfall CH, Clare-Salzler MJ, et al. Functional defects and the influence of age on the frequency of CD4+ CD25+ T-cells in type 1 diabetes. Diabetes 2005;54:1407
   PubMed Web of Science ®Google Scholar
• Grinberg-Bleyer Y, Baeyens A, You S, et al. IL-2 reverses established type 1 diabetes in NOD mice by a local effect on pancreatic regulatory T cells. J Exp Med 2010;207:1871
   PubMed Web of Science ®Google Scholar
• Tang Q, Henriksen KJ, Bi M, et al. In vitro-expanded antigen-specific regulatory T cells suppress autoimmune diabetes. J Exp Med 2004;199:1455
   PubMed Web of Science ®Google Scholar
• Lemoine FM, Cherai M, Giverne C, et al. Massive expansion of regulatory T-cells following interleukin 2 treatment during a phase I-II dendritic cellbased immunotherapy of metastatic renal cancer. Int J Oncol 2009;35:569
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Rosenberg SA. IL-2 administration increases CD4+ CD25(hi) Foxp3+ regulatory T cells in cancer patients. Blood 2006;107:2409
   PubMed Web of Science ®Google Scholar
• Siegel JP, Puri RK. Interleukin-2 toxicity. J Clin Oncol 1991;9:694
   PubMed Web of Science ®Google Scholar
• Hartemann A, Bensimon G, Payan C, et al. Low-dose interleukin-2 in patients with type-1 diabetes: a phase 1/2 randomized, double-blind, placebo-controlled trial. Lancet Diabetes Endocrinol 2013;1:295-305
   PubMed Web of Science ®Google Scholar
• Miles JJ, McCluskey J, Rossjohn J, et al. Understanding the complexity and malleability of T-cell recognition. Immunol Cell Biol 2015;93:433-41
   PubMed Web of Science ®Google Scholar
• You S, Chatenoud L. Proinsulin: a unique autoantigen triggering autoimmune diabetes. J Clin Invest 2006;116(12):3108-10
   PubMed Web of Science ®Google Scholar
• Nepom GT, Ehlers M, Mandrup-Poulsen T, et al. Anti-cytokine therapies in T1D: Concepts and strategies. Clin Immunol 2013;149(3):279-85
   PubMed Web of Science ®Google Scholar
• Long SA, Rieck M, Sanda S, et al. Rapamycin/IL-2 combination therapy in patients with type 1 diabetes augments Tregs yet transiently impairs beta-cell function. Diabetes 2012;61:2340
   PubMed Web of Science ®Google Scholar